Navigation Links
Amerigen Pharmaceuticals Limited today announced it had entered into a collaboration agreement with Forest Laboratories Inc. regarding the development of a number of specialty generic products.
Date:7/31/2013

LYNDHURST, N.J., July 31, 2013 /PRNewswire/ -- Amerigen Pharmaceuticals Limited today announced it had entered into a collaboration agreement with Forest Laboratories Inc. regarding the development of a number of specialty generic products. Under the terms of the agreement, Amerigen will use its formulation expertise to develop a range of complex generic products and will commercialize such products in the United States.  Forest will make undisclosed milestone payments to Amerigen and will receive royalties on US sales of such products.  In addition, Forest will have an option to acquire rights to register and commercialize certain products in Latin America.

John Lowry, Amerigen's President & CEO commented: "This collaboration is a testament to Amerigen's generic formulation and product development capabilities and enables the company to continue its efforts to build a portfolio of differentiated, high value generic pharmaceuticals. It also enables Amerigen to leverage its product development investments into an array of fast growing emerging markets, with the support of a leading international pharmaceutical company."

About Amerigen
Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ, USA. The group's Chinese subsidiary, the Suzhou Amerigen Pharmaceutical Company Limited, is located in Suzhou, Jiangsu Province. The group has an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA. Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.


'/>"/>
SOURCE Amerigen Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Reports Second Quarter 2013 Results
2. Anthera Pharmaceuticals Reports 2013 Second Quarter Financial Results
3. Isis Pharmaceuticals Earns $2 Million from GSK for the Advancement of ISIS-TTR Rx
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
5. Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
6. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
7. Webcast Alert: Isis Pharmaceuticals Second Quarter 2013 Financial Results Conference Call
8. Insight Pharmaceuticals Considers Bananacin -- Banana-Flavored Anacin Tablets -- After Worlds Oldest Man Credits Combo As Secret To Long Life
9. Promentis Pharmaceuticals, Inc. Appoints Industry Veteran Chad Beyer, Ph.D., MBA, as President and CEO
10. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2013 Financial Results
11. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2013 Financial Results On July 31, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical (AVACEN) ... is now successfully helping those with the widespread pain ... Fibromyalgia diagnosed Amanda in Essex, England ... washing my hair, experiencing no sleep at all, tremendous ... spasm… I cannot recommend [the AVACEN 100] enough, how ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... As health professionals ... known as “patient engagement.” The patient is doing more than filling out a survey; ... , “There is an increasing emphasis in health care and research on the importance ...
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected Warren ... James C. Puffer upon his retirement. Dr. Newton will serve in the position of ... end of 2018. Upon assuming the role of President and CEO on January 1, ...
(Date:10/13/2017)... ... 2017 , ... PurhealthRX , a leading Health and Nutrition Company, is ... to full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing ... easily incorporated into liquid products, while reducing costs to end users. , The team ...
(Date:10/13/2017)... ... , ... Lori R. Somekh, founder of the Law Office of Somekh ... law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up ... network with elder law attorneys nationwide,” said Somekh. , ElderCounsel was ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
Breaking Medicine News(10 mins):